Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Trial Profile

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Inclusion body myositis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 03 May 2017 This trial has been completed in Netherlands (end date: 13 Feb 2017).
    • 23 Mar 2017 This trial has been completed in Denmark (end date: 13 Feb 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top